Novartis AG (Novartis AG) Change In Receivables : $-1,702 Mil (TTM As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Novartis AG Change In Receivables?

Novartis AG's change in receivables for the quarter that ended in Mar. 2024 was $-920 Mil. It means Novartis AG's Accounts Receivable increased by $920 Mil from Dec. 2023 to Mar. 2024 .

Novartis AG's change in receivables for the fiscal year that ended in Dec. 2023 was $-1,504 Mil. It means Novartis AG's Accounts Receivable increased by $1,504 Mil from Dec. 2022 to Dec. 2023 .

Novartis AG's Accounts Receivable for the quarter that ended in Mar. 2024 was $7,840 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Novartis AG's Days Sales Outstanding for the three months ended in Mar. 2024 was 59.03.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Novartis AG's liquidation value for the three months ended in Mar. 2024 was $-36,133 Mil.

Novartis AG Change In Receivables Historical Data

The historical data trend for Novartis AG's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis AG Change In Receivables Chart

Novartis AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-980.00

137.00

-352.00

-397.00

-1,504.00

Novartis AG Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-700.00	-425.00	-117.00	-240.00	-920.00

Novartis AG Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1,702 Mil.

Novartis AG (NYSE:NVS) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Novartis AG's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	7840	/	12120	*	91
=	59.03

2. In Ben Graham's calculation of liquidation value, Novartis AG's accounts receivable are only considered to be worth 75% of book value:

Novartis AG's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	9694	-	54578	+	0.75 * 7840	+	0.5 * 5743
=	-36,133

Novartis AG Change In Receivables Related Terms

Thank you for viewing the detailed overview of Novartis AG's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Novartis AG (Novartis AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (NYSE:NVS) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

NVSEF:USA NVS N:Mexico NOVNz:UK 0QLR:UK NOTA:Germany NOTA:Germany NOVNEE:Switzerland NOVN:Switzerland N1VS34:Brazil NVS:Argentina

Address

Lichtstrasse 35, Basel, CHE, 4056

Website

https://www.novartis.com

Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.